ArticleFrontiers in aging neuroscience2026
Association of acute-phase plasma pTau217 levels with long-term post-stroke cognitive impairment.
Article in Frontiers in aging neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Post-stroke cognitive impairment (PSCI) is a common complication affecting stroke survivors, yet early biomarkers for risk stratification remain scarce. Plasma pTau217 has emerged as a specific biomarker for Alzheimer's disease pathology. This study explores whether acute-phase pTau217 levels are associated with PSCI. Methods: We conducted a nested case-control study including 48 patients who developed PSCI within 5 years and 48 age and sex-matched patients as controls without cognitive decline. Plasma pTau217 was measured within 24 h after stroke onset using SIMOA. Statistical analysis included multivariable logistic regression, dose-response assessment via quartile stratification, and ROC curves. Results: Plasma pTau217 levels were significantly higher in PSCI cases than controls [0.313 (0.196-0.562) vs. 0.203 (0.126-0.343) pg/mL; Conclusion: Higher acute-phase pTau217 levels were associated with an increased likelihood of clinically documented cognitive impairment during follow-up. These exploratory findings suggest that acute-phase pTau217 may be associated with long-term cognitive outcomes after stroke, although larger prospective studies, integrating additional biomarkers with standardized neuropsychological assessment are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.